Xortx Therapeutics
XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based therapies (XORLOTM) for gout patients intolerant to allopurinol and for progressive kidney diseases including ADPKD, diabetic nephropathy, and COVID-19-related kidney injury.
- Company typePublic
- Founded2012
- HeadquartersCalgary, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Xortx Therapeutics does
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company founded in 2012 and headquartered in Calgary, Canada, listed on NASDAQ under ticker XRTX (having voluntarily delisted from the TSX Venture Exchange in June 2026). The company is pre-revenue with a headcount of 1-10 employees and an accumulated deficit of approximately $23.8M as of December 31, 2025. XORTX's business is the development of proprietary small-molecule therapies based on xanthine oxidase inhibition, anchored by its XORLOTM oxypurinol formulation technology licensed from the University of Florida Research Foundation.
The pipeline is diversified across four renal and metabolic indications: XRx-026 (pre-NDA in gout for allopurinol-intolerant patients), XRx-008 (ADPKD, FDA Orphan Drug Designation), XRx-101 (COVID-19-associated kidney injury), XRx-225 (Type 2 diabetic nephropathy, pre-clinical), and the recently acquired VB4-P5 anti-fibrotic program (pre-IND). XRx-026 is advancing via the 505(b)(2) NDA pathway following a Type B meeting with the FDA in June 2026, making it the lead asset closest to potential commercialization.
The business model is a classic clinical-stage biotech: XORTX funds operations through repeated small public equity offerings — approximately $18.6M raised cumulatively since 2021, including a $5M public offering in May 2026 — with annual net losses of roughly $2.5M-$3.3M and no current licensing or product revenue. Future monetization is expected through direct commercialization or out-licensing of approved therapies to specialty or rare-disease partners, targeting addressable populations in gout (~3-5% of allopurinol-intolerant patients), ADPKD, and broader chronic kidney disease with fibrosis.
Xortx Therapeutics firmographics
Firmographics- Name
- Xortx Therapeutics
- Legal name
- XORTX Therapeutics Inc.
- Website
- https://xortx.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based therapies (XORLOTM) for gout patients intolerant to allopurinol and for progressive kidney diseases including ADPKD, diabetic nephropathy, and COVID-19-related kidney injury.
- Ownership category
- akta.pro rank
Xortx Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals (Nephrology and Gout)
- NAICS
- Medical and Diagnostic Laboratories (6215), Kidney Dialysis Centers (621492)
- SIC
- Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Xortx Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Calgary
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Xortx Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Pharmaceutical Product Sales: Pre-revenue company. Will generate revenue through commercialization of prescription pharmaceutical products targeting gout and kidney diseases upon FDA approval. The lead product XRx-026 targets a US$700 million per year market opportunity.
- Licensing Royalties: Company has licensing agreement with University of Florida Research Foundation Inc. for intellectual property related to xanthine oxidase inhibition technology.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Xortx Therapeutics product offering
Product offeringCore offering
XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based (XORLOTM) uric acid-lowering therapies for gout and progressive kidney disease. The lead program XRx-026 is at pre-NDA filing for gout patients intolerant to allopurinol (3-5% of patients), with additional programs targeting ADPKD (XRx-008, Orphan Drug Designation), acute kidney injury from respiratory viruses (XRx-101), and Type 2 Diabetic Nephropathy (XRx-225). The company acquired the VB4-P5 kidney anti-fibrotic program from Vectus Biosystems in April 2026.
Product overview
XORTX Therapeutics is a late-stage clinical pharmaceutical company developing a pipeline of uric acid-lowering agents targeting aberrant purine metabolism. The company has four core programs: XRx-026 (pre-NDA stage for gout), XRx-008 (Phase 3 planned for ADPKD, Orphan Drug Designation), XRx-101 (Phase 3 planned for acute kidney injury from respiratory viruses), and XRx-225 (pre-clinical for Type 2 Diabetic Nephropathy). The company also acquired VB4-P5 (pre-IND kidney anti-fibrotic). All programs utilize the proprietary oxypurinol formulation XORLOTM to inhibit xanthine oxidase and reduce uric acid production. One program is at pre-NDA filing stage, two are in clinical development, and one is at early pre-clinical stage.
Differentiator
Problem solved
Functional benefit
Products and services
- XRx-026
Quantifiable outcome
- US$700 million per year target market opportunity for XRx-026 in gout patients intolerant to allopurinol
- +2 more outcomes
Companies that use Xortx Therapeutics
Customer profileSegments5 records
Ideal customer profiles2 records
Xortx Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Xortx Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Vectus Biosystems LimitedcoreXortx acquired the Renal Anti-Fibrotic Therapeutic Program including novel chemical entity VB4-P5, associated intellectual property, regulatory documentation, and manufacturing data. Deal valued at US$3.0 million paid through 154,544 common shares and 692,150 pre-funded warrants. The program targets both rare and prevalent forms of chronic kidney disease characterized by fibrosis.
- University of Florida Research Foundation Inc. (UFRF)coreLicensing agreement for intellectual property related to xanthine oxidase inhibition technology and related compounds. The technology was developed by Dr. Richard Johnson and Dr. Takahiko Nakagawa. License agreement covers technology for treating conditions modulated by aberrant purine metabolism.
Scale indicators11 records
Recent moves8 records
Expansion highlights5 records
Xortx Therapeutics competitors and assessment
Company assessmentDirect peers
- ProKidney: Clinical-stage cell therapy company (rilparencel) targeting chronic kidney disease and diabetic kidney disease. Comparable as a small-cap, late-clinical nephrology-focused biotech pursuing CKD indications.
- Selecta Biosciences (now Cartesian Therapeutics): Was a clinical-stage immunology company developing SEL-212 (pegadricase + rapamycin) for refractory gout. Comparable as a small clinical-stage biotech directly addressing the same allopurinol/febuxostat-intolerant gout segment that XRx-026 targets.
- Travere Therapeutics: Small clinical-stage rare disease company with approved kidney drug Filspari (sparsentan) for IgA nephropathy and FSGS. Highly comparable given similar size, kidney-disease focus, and specialty pharma commercial model.
- Chinook Therapeutics (acquired by Novartis): Clinical-stage nephrology company developing treatments for ADPKD and IgA nephropathy (atrasentan, zigakibart) prior to its 2023 acquisition by Novartis. Directly comparable to XORTX's ADPKD program XRx-008 in target indication and stage.
Broad incumbents
- Otsuka Pharmaceutical: Large Japanese pharma with Jynarque (tolvaptan) — the only FDA-approved therapy to slow ADPKD progression. Directly competes with XORTX's XRx-008 in the ADPKD indication, though Otsuka operates across many other therapeutic areas.
- Amgen (Horizon Therapeutics): Amgen acquired Horizon Therapeutics in 2023, gaining Krystexxa (pegloticase) for refractory/chronic gout. Directly relevant to XORTX's XRx-026 target patient population (treatment-refractory gout), though Amgen is a broad large-cap incumbent.
Emerging players
- Galapagos NV: European clinical-stage biotech that pivoted toward CAR-T and renal disease programs after restructuring. Comparable as a smaller biotech strategically reorienting toward nephrology indications similar to XORTX's pipeline.
- Swedish Orphan Biovitrum (Sobi): Specialty rare-disease biotech with presence in gout and inflammatory diseases (Kineret, caspofungin). Comparable as a specialty pharma pursuing orphan and rheumatology indications overlapping with XORTX's nephrology/gout focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Xortx Therapeutics social profiles
Digital presenceXortx Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xortx Therapeutics leadership team
Management profileNumber of profiles
Profiles9 records
Xortx Therapeutics funding detail
Funding detailFunding overview
Funding rounds9 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xortx Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xortx Therapeutics
What does Xortx Therapeutics do?
XORTX Therapeutics is a late-stage clinical pharmaceutical company developing proprietary oxypurinol-based (XORLOTM) uric acid-lowering therapies for gout and progressive kidney disease. The lead program XRx-026 is at pre-NDA filing for gout patients intolerant to allopurinol (3-5% of patients), with additional programs targeting ADPKD (XRx-008, Orphan Drug Designation), acute kidney injury from respiratory viruses (XRx-101), and Type 2 Diabetic Nephropathy (XRx-225). The company acquired the VB4-P5 kidney anti-fibrotic program from Vectus Biosystems in April 2026.
Is Xortx Therapeutics a public or private company?
Xortx Therapeutics is a public company. It is classified as public and is currently operating.
When was Xortx Therapeutics founded?
Xortx Therapeutics was founded in 2012. It employs 1 to 10 people.
Where is Xortx Therapeutics based?
Xortx Therapeutics is headquartered in Calgary, Canada, in the North America region.
How does Xortx Therapeutics make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Royalties.
Who are Xortx Therapeutics's main competitors?
Direct peers on record are ProKidney, Selecta Biosciences (now Cartesian Therapeutics), Travere Therapeutics and Chinook Therapeutics (acquired by Novartis). Broad incumbents are Otsuka Pharmaceutical and Amgen (Horizon Therapeutics). Emerging players are Galapagos NV and Swedish Orphan Biovitrum (Sobi).
Does Xortx Therapeutics have an API?
No public API is recorded for Xortx Therapeutics.
What industry is Xortx Therapeutics in?
Xortx Therapeutics's product category is Specialty Pharmaceuticals (Nephrology and Gout). Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 6215 and its SIC code is 2834.